Markets
Plans Sign in
APP →

Amgen (AMGN) stock

Stock · prices in USD

Next quarterly results

Estimated around Feb 2, 2027 (in 80 days)

Estimated from the company's previous report dates; the official date is announced by the company.

Is it growing?

Revenue from SEC filings · fiscal 2022–2025

Revenue growth per year (3 fiscal years)+11.8%
Latest quarter vs a year earlier+8.5%quarter ended Sep 30, 2026

Does it make money?

Margins, cash and debt from SEC filings

Net margin21.0%fiscal 2025 · range 12.2%–24.9% over 4 years
Operating margin24.7%fiscal 2025
Free cash flow, last 12 months$9.58Bto Sep 30, 2026
Diluted shares, 3-year change+0.2%
P/E (12 months)27.04 quarters to Sep 30, 2026
1-year and 5-year range in the app 

Price ÷ diluted earnings per share of the last 4 quarters to Sep 30, 2026 (SEC filing of Nov 4, 2026). Price as of Nov 14, 2026, 19:50 UTC. A descriptive ratio: it does not say whether a stock is worth buying, and one-off or restated earnings can distort it.

Source: filings submitted to the SEC (EDGAR) and delayed market data. Errors or delays are possible; results dates are estimates. Educational only.

Price facts

Latest delayed quote: $465.67, -0.44% versus the previous close (checked at 19:50 UTC on Nov 14, 2026).

Last close: $460.42 on Nov 6, 2026.

52-week closing range: $313.85 to $478.48. The last close sits 89% of the way from the low to the high.

Change over

30 days+11.5%
90 days+12.0%
1 year+43.8%

Recent 3-month volatility is higher than usual compared with its own history since 2021 (97th percentile).

Delayed data. Past moves do not indicate future results.

Create a free account and get 3 AI analyses: reaction zones, macro scenarios and your timeframe.

Try GeekAlpha free: 3 analyses, no card

You're signed in. Open the app to analyze AMGN.

Open the app

Go further on AMGN

Details and limits

From the company filings

Revenue grew on average 11.8% a year over the last 3 fiscal years (FY2022: $26.32B → FY2025: $36.75B).

In the latest quarter (ended Sep 30, 2026) revenue was $10.37B, +8.5% versus the same quarter a year earlier.

Source: company filings on SEC EDGAR, latest filed Nov 4, 2026, data through Sep 30, 2026.

SEC industry classification: Biological Products, (No Diagnostic Substances). Fiscal year ends December 31. Listed on Nasdaq.

Limits of this information